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Introduction
Translational bioinformatics is a rapidly emerging field of
biomedical data sciences and informatics technologies that
efficiently translate basic molecular, genetic, cellular, and
clinical data into clinical products or health implications.
Translational bioinformatics is now even more powerful
than ever. The revolutionary progress in both bioinfor-
matics and high-throughput genomics based on the flood
of nucleotide sequences and microarray data will even-
tually transform the current practice of medicine forever,
including diagnostics, therapeutics, and prognostics.
Translational research is a paradigm for an alternative
research approach to the dichotomy of basic and applied
research. Its cross-disciplinary nature is a serious chal-
lenge caused by the compartmentalization of the current
research training paradigm. Moreover, bioinformatics
itself is interdisciplinary. To understand and correctly
address the clinical needs for ultimately improving
human health requires strategically-minded scientists,
multi-skilled teams, and knowledge-driven data infra-
structure for integrative analytics. Despite the barriers,
linking the molecular world to the clinical world and vice
versa will enormously benefit human health.
Since its inception, the Translational Bioinformatics
Conference (TBC) aims to highlight the multi-disciplinary
nature of the research field and provides an opportunity to
bring together and exchange ideas between international
translational bioinformatics researchers. The Second
Annual TBC 2012 in Jeju Island of South Korea provided
the opportunity to substantially improve the understand-
ing of complex and rare diseases and proposed new ways
of approaching basic health problems by integrating geno-
mic and clinical data.
Personalized genomic and physiologic signatures
Translational bioinformatics together with the ‘-omics’
(genomics, transcriptomics, proteomics, and metabolo-
mics) investigates the contribution of genes, transcripts,
proteins, and metabolic pathways to human physiology
and the variations of its sub-systems that can lead to dis-
ease susceptibility. While a plethora of genomic signa-
tures have successfully demonstrated their predictive
power with diagnostic and prognostic values in many
cancers, these genomic signatures are, as Chen et al.
(University of Chicago, USA) correctly pointed out,
merely statistically significant differences between dichot-
omized phenotypes that are in fact severely heteroge-
neous [1].
Personalized medicine attempts to determine indivi-
dual solutions based on the susceptibility profiles of
each individual. Based on their previous research on
FAIME (Functional Analysis of Individual Microarray
Expression, [2]) method, Chen et al. generated pathway
signatures for an individual patient and computed aggre-
gate ‘molecular-pathway’ scores using rank-weighted
gene expression values of an individual sample. FAIME
not only improved the predictive power but also pro-
vided personalized pathway profiles that have potential
for the personalized therapeutics of cancer.
To overcome the limitations of population-based medi-
cine, both personalized physiologic and genomic signature
are introduced in this issue. Grossman et al. (Stanford
University, USA) constructed Spearman correlation net-
works of pairs of 29 physiologic variables measured at
one-minute intervals from nineteen intensive care unit
patients [3]. According to the connection changes in the
presence and absence of pressor drug administrations, the
networks can be divided into ‘static’, ‘either-or’, and ‘sign-
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change’ networks that permit individual patient-level ana-
lysis of physiological states. While the ‘static’ networks
represent known normative physiological relations not
associated with pressors, the others represent new physio-
logical relations sensitive to pressors and/or to the reasons
for giving the drugs.
Dynamic network biomarkers and
pathophysiological correlates
Biomarkers are indicators of biological states that are
useful for the evaluation of physiological states, patho-
genic processes, and therapeutic responses. Perturba-
tions between two biological states, however, lie at the
network level and not at any one molecular biomarker.
Genomic data has the potential to reveal dynamic rela-
tions between genes during temporal progressions.
While traditional biomarkers are mainly used to exam-
ine only the current disease status based on a single
molecule, Liu et al. (Shanghai Institutes for Biological
Sciences, China) defined a new type of biomarker, i.e.,
dynamical network biomarker, for marking the time per-
iod just before the catastrophic state transitions between
normal state, pre-disease state, and disease state [4]. By
using temporal gene expression profiles of non-obese
diabetic mouse, Liu et al. successfully identified dynami-
cal network biomarkers that distinguish the pre-disease
state from the normal state and predict the upcoming
disease onset of type-I diabetes by the theory of early-
warning signals of complex diseases [5].
Penrod and Moore (Dartmouth College, USA) created
temporal gene coexpression networks from sequential
biopsy samples of breast cancer patients at diagnosis
(pre-treatment), following 10-14 days (mid-treatment),
and following 90 days of letrozole treatment (post-treat-
ment) [6]. They showed that the breast tumor coexpres-
sion networks are extensively rewired to adapt to the
perturbation in the course of letrozole treatment and
identified biomarkers maintaining network integrity and
controlling information flow. It is suggested that many of
the key genes for modulating the information flow at
each of three time points are specific to the perturbation
conditions.
Network biomarkers can be directly associated with
clinically significant phenotypes. Yim et al. (Ajou Univer-
sity, Korea) investigated the gene expression profiles of 23
patients with congenital muscular torticollis and 5 control
tissues [7]. Differentially expressed genes and protein net-
work modules were identified as the prominent biomar-
kers showing strong correlation with the disease severity
quantitatively measured by pre-operational MRI images.
Pathophysiologic mechanisms suggested by molecular
genomic features can be well translated to gross anatomi-
cal features.
Knowledge assembly for drug repositioning and
rare variant interpretation
Public databases and numerous biomedical knowledge
resources are invaluable for a high profile translational
bioinformatics research. They lead researchers to a bet-
ter understanding and interpretation of clinical and
genomic data that cannot be achieved by numeric data
analysis alone. Hard problems like drug repositioning
and rare variant interpretation can be successfully
addressed by systematically borrowing the power of bio-
medical knowledge assembly. Cheung et al. (University
of British Columbia, Canada) predicted drug-disease
associations by evaluating the over-representation of
Medical Subject Heading (MeSH) terms for chemical
compounds assigned to diseases- or symptom-related
research publications in the MEDLINE database [8].
Moore et al. (Vanderbilt University, USA) developed a
flexible collapsing method guided by biological knowl-
edge and created a comprehensive biomedical knowledge
repository (LOKI, Library of Knowledge Integration) for
supporting systematic multi-level binning of low fre-
quency DNA variants for association testing [9]. LOKI
determines the boundaries of the bins for rare variants by
functional regions, evolutionarily conserved regions,
genes, pathways, and/or intergenic regions in a flexible
and user-defined fashion. One can choose statistical tests
according to the hypothesis being tested for the under-
standing of the role of rare variation in complex human
disease.
Methods for further translation
Better bioinformatics tools and methods are required for
a successful translational research. In this issue,
advanced solutions for well-known bioinformatics pro-
blems were introduced. Kim et al. (CHA University,
Korea) proposed a novel algorithm to combine haplo-
type clusters for diplotype-based association studies [10].
Van de Wiel et al. (VU University, Netherlands) devel-
oped a Baysian method for shrinking multiple para-
meters in a statistical model [11]. They applied the
method to high-throughput RNA interference screening
experiments to overcome the small sample size by bor-
rowing information across the feature dimension. Kim
et al. (Sookmyung Women’s University, Korea) extended
the multifactor dimensionality reduction (MDR) algo-
rithm that is currently limited to binary traits [12] to
traits having ordinal features in an attempt to advance
further gene-gene interaction analysis [13].
This meeting, TBC 2012, provided the opportunity for
translational bioinformatics researchers to bring together
and substantially improve the understanding of complex
human diseases for personalizing healthcare. We learned
that our ‘personal-level’ understanding of physiologic
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and bio-molecular foundations is severely limited. It is
clear that many health topics are now within the scope
of translational bioinformatics, including complex
human disease, medical genetics, cancer, drug reposi-
tioning, and response to therapeutic perturbations.
There are many barriers to translating our molecular
understanding into meaningful products. Effectively
integrating biomedical data and knowledge resources
with powerful algorithms is even more important than
ever. I congratulate the speakers and authors to this
conference who are shaping the future of how biomedi-
cal informatics translates into better practice. The future
of translational bioinformatics, as William Gibson said,
is already here, it’s just not widely and evenly distributed
yet.
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